BBIO
BridgeBio Pharma, Inc.
September 15, 2026 · intraday
- Rarity
- 1.68
- Peak move
- −7.39%
- Float cap
- $12.1B
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and delivers medicines for patients with genetic diseases and other significant unmet medical needs. Its approved products include Attruby (acoramidis) for transthyretin amyloid cardiomyopathy, marketed in the United States, and Beyonttra ex-U.S. through partners, plus Nulibry for molybdenum cofactor deficiency Type A. It also advances late-stage therapies for rare and genetically defined conditions.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
2 events · 0 from SEC or newswire · 0 timed with the moveexecutive_remarkAt the Morgan Stanley 24th Annual Global Healthcare Conference on Sept 15, BridgeBio management including COO Julie Everett and CBO Chinmay Shukla discussed Attruby's growth outlook with about $25-30M sequential quarterly growth and $4B peak-year sales potential, oral infigratinib's 30-40% peak U.S. market share opportunity in achondroplasia, BBP-418's Nov 27 PDUFA and encaleret, and positioning for generic tafamidis entry in early 2032, while noting its equity cost of capital remains too high.
regulatory_approvalBridgeBio Pharma announced a voluntary agreement with the U.S. government to expand state Medicaid access to Attruby (acoramidis) through the GENEROUS model and continue offering it via Medicare Part D without future pricing mandates, with confidential terms.